Insight

Yüksel Ürün: U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Photo from Yüksel Ürün/X

Aug 4, 2024, 05:15

Yüksel Ürün: U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Yüksel Ürün shared on X:

“U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy.

Approved with carboplatin/paclitaxel, then single-agent dostarlimab-gxly, for primary advanced/recurrent endometrial cancer.
Median OS 44.6 months vs. 28.2 months.
Common adverse reactions: anemia, fatigue, neuropathy.”

Yüksel Ürün

Source: Yüksel Ürün/X

Other posts featuring Yüksel Ürün on OncoDaily.

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

anemia Ankara University School of Medicine cancer cancer indication carboplatin chemotherapy fatigue neuropathy OncoDaily Oncology Paclitaxel Research U.S. FDA Yüksel Ürün

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage